BioPlus Acquisition Corp.
BIOS
NASDAQ Global Market10.80
USD
+0.00
- -
CIK
0001856653
ISIN
KYG112171171
CUSIP
09069N108
Return %
Stock
S&P500
1Y
6.56
18.21
3Y
10.15
64.38
5Y
10.15
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- R. Ross Haghighat
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 260 Madison Avenue New York City NY United States of America 10026
- IPO Date
- Jan 28, 2022
- CIK
- 0001856653
- Website
- bioplusspac.com
- Similar Companies
- Business
- BioPlus Acquisition Corp. functioned as a blank check company, formed with the explicit purpose of engaging in a business combination, like a merger or asset acquisition, with one or more enterprises in the life sciences industry. The entity was established in 2021 and maintained its headquarters in New York, New York. However, as of October 4, 2023, the company announced the mutual termination of its prospective business combination agreement with Avertix Medical, Inc. Subsequently, BioPlus Acquisition Corp. declared its intention to liquidate its operations and initiate the process of returning funds to holders of its public shares.
COMPUTEX 2026: MiTAC Advances Diversified AI Infrastructure Through Strategic Ecosystem Partnerships
BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate
Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation
BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offering
Option Care Health Completes Reverse Stock Split and Ticker Symbol Change